In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

New images of the interstellar object 3I/ATLAS have captured an astonishing, multi-jet structure, with vast plumes extending millions of kilometers into space. The discovery, observed by Frank ...

Creating simple data classes in Java traditionally required substantial boilerplate code. Consider how we would represent Java’s mascots, Duke and Juggy: public class JavaMascot { private final String ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Beijing Zhongke Journal Publising Co. Ltd. The lead author Cheng-Zhi Qin, a professor of geographical information science (GIS) at Institute of Geographic Sciences and Natural Resources Research, ...